Expression of phosphorylated ribosomal protein s6 in mesothelioma patients – correlation with clinico-pathological characteristics and outcome: results from the european thoracic oncology platform (etop) mesoscape project

HIGHLIGHTS

SUMMARY

A statistically significant difference in OS for the pS6 status was observed only in non-epithelioid patients (p and amp;lt; 0.001), with median OS 10.7 months (95% CI: 7.4-13.6) for pS6 high versus 16.9 months (95% CI: 11.5-22.7) for patients with pS6 low expression. In both high and low pS6 groups, histology was a significant prognostic factor with favourable outcome for epithelioid patients: HRepithelioid vs. non-epithelioid=0.26 (95% CI: 0.18-0.38); p and amp;lt; 0.001 in pS6 high . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.